UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~July~~August 285, 2025

Imunon, Inc.

(Exact name of registrant as specified in its Charter)

Delaware

001-15911

52-1256615

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

997 Lenox Drive, Suite 100, Lawrenceville, NJ		08648-2311
(Address of principal executive offices)		(Zip Code)

(609) 896-9100

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		IMNN		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 82.0102 ~~Other~~Results ~~Events~~of Operations and Financial Condition.

On ~~July~~August 285, 2025, Imunon, Inc. ~~(the “Company”),~~ issued a press release ~~announcing~~reporting ~~that~~its ~~the~~financial ~~Company’s~~results ~~Board~~for ofthe ~~Directors approved~~quarter aended ~~15%~~June ~~stock dividend~~30, 02025.15 ~~shares~~A ofcopy ~~common stock (the “Stock Dividend”) per share~~ of the ~~Company’s issued~~ ~~and~~press ~~outstanding~~release ~~shares~~is offurnished ~~common~~as ~~stock,~~Exhibit ~~par value $0~~99.011 ~~per~~to ~~share~~this ~~(the~~Current ~~“Common~~Report ~~Stock”),~~on ~~and~~Form ~~per each common stock equivalent with dividend rights~~8-K.

~~The~~On ~~Board~~July of29, ~~Directors~~2025, ~~has~~Imunon, ~~fixed~~Inc. announced it would hold a conference call on August 75, 2025 asto ~~the~~discuss ~~record~~its ~~date~~financial ~~(the~~results ~~“Record Date”)~~ for the ~~Stock~~quarter ended ~~Dividend~~June 30, 2025 and ~~the~~provide ~~Stock Dividend~~a ~~will~~business beupdate. ~~payable~~The onconference ~~August~~call ~~21,~~will ~~2025~~also tobe ~~stockholders~~broadcast oflive ~~record~~on ~~as of~~ the ~~Record~~internet ~~Date~~at http://www.imunon.com.

The information ~~contained~~ in ~~Exhibit~~this ~~99.1~~report, isincluding ~~intended~~the toexhibit behereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, ~~(the~~as ~~“Exchange~~amended, ~~Act”)~~ or otherwise subject to the liabilities of that ~~section,~~Section ~~nor~~or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. Such information shall itnot be ~~deemed~~ incorporated by reference ininto any filing ~~under~~ with the Securities ~~Act~~and ofExchange ~~1933~~Commission made by Imunon, Inc., whether made before or after the ~~Exchange~~date ~~Act~~hereof, regardless of any general incorporation language in such filing.

The press release contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated ~~July~~August 285, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMUNON INC.
Dated: July 28, 2025	By:	/s/ Susan Eylward
Dated: August 5, 2025	By:	/s/ Kimberly Graper
		Susan Eylward
		Kimberly Graper
		General Counsel and Corporate Secretary
		Chief Financial Officer

Filing Compare · Imunon, Inc.